Related Experiment Video
Updated: Jul 2, 2025

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
Ligandability assessment of the C-terminal Rel-homology domain of NFAT1
Jark Böttcher1, Julian E Fuchs1, Moriz Mayer1
1Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Abstract:
Transcription factors are generally considered challenging, if not "undruggable", targets but they promise new therapeutic options due to their fundamental involvement in many diseases. In this study, we aim to assess the ligandability of the C-terminal Rel-homology domain of nuclear factor of activated T cells 1 (NFAT1), a TF implicated in T-cell regulation. Using a combination of experimental and computational approaches, we demonstrate that small molecule fragments can indeed bind to this protein domain. The newly identified binder is the first small molecule binder to NFAT1 validated with biophysical methods and an elucidated binding mode by X-ray crystallography. The reported eutomer/distomer pair provides a strong basis for potential exploration of higher potency binders on the path toward degrader or glue modalities.
Insights
Researchers identified small molecule fragments that bind to the nuclear factor of activated T cells 1 (NFAT1) protein domain. This finding opens new therapeutic avenues for diseases involving NFAT1, a challenging transcription factor target.
Area of Science:
- Biochemistry
- Structural Biology
- Drug Discovery
Background:
- Transcription factors are crucial disease regulators but often considered undruggable targets.
- Nuclear factor of activated T cells 1 (NFAT1) plays a key role in T-cell regulation and related diseases.
Purpose of the Study:
- To assess the ligandability of the C-terminal Rel-homology domain of NFAT1.
- To identify small molecule binders for NFAT1.
Main Methods:
- Utilized a combination of experimental and computational approaches.
- Employed biophysical validation methods.
- Determined the binding mode using X-ray crystallography.
Main Results:
- Demonstrated that small molecule fragments can bind to the NFAT1 protein domain.
- Identified the first validated small molecule binder for NFAT1.
- Elucidated the binding mode of the identified binder.
Conclusions:
- The C-terminal Rel-homology domain of NFAT1 is druggable.
- The identified binder and its eutomer/distomer pair serve as a foundation for developing potent NFAT1-targeting therapeutics.
- This research paves the way for novel degrader or glue modalities for NFAT1-related diseases.
More Related Videos
10:05Visualization of Protein-protein Interaction in Nuclear and Cytoplasmic Fractions by Co-immunoprecipitation and In Situ Proximity Ligation Assay
Published on: January 16, 2017
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Co-activators and Co-repressors
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...